News & Media

News

July 10, 2024

Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne Syndrome

COLUMBUS, OH, July 10, 2024 – Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and...

News & Media

June 11, 2024

UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

UMass Chan Medical School has received $2.2 million from a nonprofit patient-advocacy organization to contract with Andelyn Biosciences to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.

News

May 23, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC)

COLUMBUS, OH, May 23, 2024 – Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and...

News

March 25, 2024

Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency

COLUMBUS, OH, March 25, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News

February 28, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)

COLUMBUS, OH, February 28, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News & Media

February 23, 2024

Andelyn Biosciences Announces New Chief Operations Officer

(COLUMBUS, Ohio) – Andelyn Biosciences announces the promotion and appointment of Cyrill Kellerhals as Chief Operations Officer (COO). Cyrill will lead...

News

January 15, 2024

Andelyn Biosciences and Armatus Bio Partner to Manufacture Suspension-Based AAV Gene Therapy for Rare Neurological Disease Charcot-Marie-Tooth Type 1A (CMT1A)

COLUMBUS, OH, January 15, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

Blog

December 22, 2023

Three perspectives on the challenges and trends in gene therapy

In this blog, three experts in the field of gene therapy from Andelyn Biosciences give their perspectives on challenges and...

News

December 18, 2023

Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome

Columbus, OH, December 18, 2023 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News

November 20, 2023

Battelle, Andelyn Biosciences, and AmplifyBio Awarded Task Orders for Plasmid and Suspension AAV Vector Manufacturing and IND-enabling Studies from the National Institute of Neurological Disorders and Stroke (NINDS)

COLUMBUS, OH, Nov 20, 2023 – Battelle, Andelyn Biosciences, Inc., and AmplifyBio, have been awarded a new task order from the...

Connect Here With Our Business Team